Is INMD a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Demand stabilization and the rate cycle, with revenue trend at Roughly $365 to $375 million guided for 2026, near 2025's ~$370 million; well below the prior peak after a sharp 2024 decline and a further modest slip in 2025. The bear case rests on the central risk is that aesthetic capital equipment is highly discretionary and cyclical, so demand is sensitive to interest rates, credit availability, and consumer spending, and revenue has already fallen well below its peak. Analysts covering it are spread from $14.00 to $17.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The central risk is that aesthetic capital equipment is highly discretionary and cyclical, so demand is sensitive to interest rates, credit availability, and consumer spending, and revenue has already fallen well below its peak. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $14.00, -7.5% from the $15.13 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Demand stabilization and the rate cycle. InMode's near-term story hinges on whether aesthetic-device demand stabilizes. The most optimistic analyst target on INMD is $17.00, +12.4% from the $15.13 price. That figure is only reachable if this thesis works close to its best case.

The central risk is that aesthetic capital equipment is highly discretionary and cyclical, so demand is sensitive to interest rates, credit availability, and consumer spending, and revenue has already fallen well below its peak. Competition is a second major risk: injectables such as Botox and dermal fillers, plus GLP-1 weight-loss drugs, compete for the same patients and budgets, and rival device makers like Cutera, Cynosure, Sciton, and Candela contest the market. InMode is based in Israel, adding geopolitical and currency risk, and it faces medical-device regulation across many jurisdictions. Large buybacks return cash but do not fix demand, and if the downturn persists longer than expected, a low multiple could stay low. Reliance on a concentrated set of RF platforms also leaves the company exposed if newer technologies or treatments erode the appeal of its core procedures. The most pessimistic published target is $14.00, -7.5% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

InMode Ltd is a medical-aesthetics company based in Yokneam, Israel, that develops and sells energy-based platforms for minimally invasive and non-invasive procedures.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Demand stabilization and the rate cycle) stalling in the reported numbers rather than in the narrative, the risk above (the central risk is that aesthetic capital equipment is highly discretionary and cyclical, so demand is sensitive to interest rates, credit availability, and consumer spending, and revenue has already fallen well below its peak) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is very high margins, a large cash balance, aggressive buybacks, and a low earnings multiple if aesthetic demand recovers. The bear case is a multi-year revenue decline driven by high rates, soft discretionary spending, and competition from injectables and GLP-1 drugs, with no clear near-term growth catalyst. Weigh both against your portfolio rather than anchoring on the low multiple.

InMode designs and sells energy-based medical-aesthetics platforms, mainly radiofrequency systems, used by physicians for minimally invasive and non-invasive procedures. Flagship products include Morpheus8 for RF microneedling, BodyTite and FaceTite for RF-assisted contouring, and EvolveX for non-invasive body treatments. It sells the devices to dermatologists, plastic surgeons, and other practices, and earns recurring revenue from consumables and service across a large installed base.

InMode sells expensive capital equipment to aesthetic practices, which is highly sensitive to interest rates and discretionary spending. Higher rates made it costly for practices to finance new devices, and softer consumer demand reduced procedure volumes. Competition from injectables and GLP-1 weight-loss drugs for the same patients added pressure. Revenue fell sharply in 2024 and slipped further in 2025, with 2026 guidance pointing to stabilization rather than renewed growth.